Meropenem and Japanese Antibiotics: A Procurement Guide for International Buyers

Japan as a Source for Antibiotic and Anti-Infective Products

Japan’s pharmaceutical industry has a long-established position in the development and manufacture of antibiotics and anti-infective agents. Japanese pharmaceutical companies—including Meiji Seika Pharma, Shionogi, and Daiichi Sankyo—have been significant contributors to the global antibiotic supply chain, manufacturing products that are distributed both domestically and internationally.

For international hospital procurement teams, infection control pharmacists, and healthcare supply managers, Japan-origin antibiotics represent a quality-assured option—particularly for products where supply from traditional European or US manufacturers is constrained, or where specific formulations are required.

Key Antibiotic Categories Available from Japan

Carbapenems: Meropenem

Meropenem is a broad-spectrum carbapenem antibiotic used in hospital settings for severe infections including pneumonia, intra-abdominal infections, meningitis, and infections caused by multidrug-resistant organisms. Meiji Seika Pharma is a significant Japanese manufacturer of meropenem, producing both intravenous infusion and intravenous bag formulations.

International procurement teams searching for meropenem sourcing options will find Meiji Seika Pharma products listed in the J-Lex database (db.tasakipharma.com), searchable by active ingredient or manufacturer name.

Fluoroquinolones

Japan has approved multiple fluoroquinolone antibiotics including levofloxacin, prulifloxacin, and garenoxacin. Formulations from Japanese manufacturers such as Daiichi Sankyo (Cravit / levofloxacin) and Meiji Seika Pharma are available for international procurement.

Antifungals

Ketoconazole cream and lotion formulations, as well as certain systemic antifungal preparations, are available from Japanese manufacturers. Ketoconazole 2% formulations appear regularly in international procurement enquiries directed at Japan-based exporters.

Fosfomycin

Fosfomycin—increasingly important in the context of multidrug-resistant infection management—is manufactured by Meiji Seika Pharma in Japan. Both oral and intravenous formulations are available and are accessed internationally, particularly in markets facing supply constraints for this agent.

Cephalosporins and Penicillins

Japan has a broad base of approved cephalosporin and penicillin-class antibiotics, including formulations from manufacturers such as Meiji Seika Pharma, Shionogi, and others. These include standard oral and injectable formulations relevant to hospital pharmacy procurement.

Why Source Antibiotics from Japan?

• PIC/S GMP compliance: Japanese antibiotic manufacturers operate under manufacturing standards recognised by regulatory authorities in over 50 countries.
• Established manufacturing base: Japan’s antibiotic production capacity is well-established, with manufacturers producing for both domestic and export markets.
• Supply diversification: Adding Japan-origin antibiotics to an approved supplier list reduces dependence on single geographic sources—increasingly important given global supply chain disruptions.
• Specific formulation availability: Certain formulations, concentrations, or packaging configurations may be available from Japanese manufacturers where they are not locally produced.

Regulatory Considerations

Antibiotics are widely licensed medicines in most markets. Importation of Japanese-origin antibiotic formulations not holding local Marketing Authorisation typically proceeds under the standard unlicensed import framework:

• UK: WDA(H) importer licence; MHRA Specials notification (28 days before first import)
• Australia: TGA Special Access Scheme
• Singapore: HSA Special Access Route

Documentation Available

• Certificate of Origin (CoO)
• Certificate of Analysis (CoA) with batch-level quality data
• Package insert / Patient Information Leaflet
• GDP compliance documentation
• Manufacturer GMP certificate (PIC/S)

Finding Japanese Antibiotic Products: J-Lex Database

J-Lex (db.tasakipharma.com) provides an English-language searchable database of Japan-approved ethical medicines. Search by active ingredient (e.g., meropenem, fosfomycin, levofloxacin) or manufacturer (e.g., Meiji Seika Pharma) to confirm product availability and formulation details.

How TASAKI PHARMA Supports Antibiotic Procurement

TASAKI PHARMA is a Taiwan-based pharmaceutical trading company with GDP and PIC/S GMP-compliant operations, experienced in supplying Japanese pharmaceutical products—including anti-infective agents—to healthcare institutions internationally.

• Meropenem, fosfomycin, fluoroquinolones, and other Japan-approved antibiotics available via J-Lex
• CoO, CoA, and product documentation upon request
• GDP-compliant logistics with appropriate cold chain management
• Ex Works pricing in USD, EUR, or JPY

For antibiotic sourcing enquiries, visit tasakipharma.com or search J-Lex at db.tasakipharma.com.